Core Insights - Moderna reported a quarterly loss of $2.50 per share, which was better than the Zacks Consensus Estimate of a loss of $2.69, and a significant decline from earnings of $0.55 per share a year ago, indicating a 7.06% earnings surprise [1] - The company generated revenues of $966 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.04%, but down from $2.81 billion in the same quarter last year [2] - Moderna has consistently exceeded consensus EPS estimates over the last four quarters, with a notable surprise of 101.59% in the previous quarter [2][1] Financial Performance - The stock has underperformed, losing approximately 23.2% since the beginning of the year, while the S&P 500 has gained 4% [3] - The current consensus EPS estimate for the upcoming quarter is -$2.85, with expected revenues of $234.83 million, and for the current fiscal year, the estimate is -$8.72 on $2.3 billion in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Moderna belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of Moderna's stock may be influenced by the overall industry outlook, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Insights - Moderna reported fourth-quarter revenue that exceeded estimates but experienced a larger-than-expected net loss, indicating ongoing challenges as the company adapts to declining demand for its Covid vaccine and seeks to launch new products [1][2] Financial Performance - The company posted a net loss of $1.12 billion, or $2.91 per share, for Q4 2024, compared to a net income of $217 million, or 55 cents per share, in the same period last year [2] - Fourth-quarter sales were $966 million, significantly down from $2.8 billion in the prior year, with Covid vaccine sales contributing $923 million, a 66% decrease year-over-year [6][10] - The loss per share was higher than the expected loss of $2.68, while revenue slightly surpassed the expected $942.8 million [9] Cost Management - The company reduced costs by 27% compared to 2023 and aims to cut costs by an additional $1 billion by the end of 2025 [3] - Cost of sales for Q4 was $739 million, down 20% from the previous year, including $193 million in writedowns of unused Covid vaccine doses [12] Product Sales and Guidance - Moderna reiterated its full-year 2025 product sales guidance of $1.5 billion to $2.5 billion, with expectations of only $200 million in sales during the first half of the year due to seasonal demand [4] - The company previously slashed its 2025 sales guidance by approximately $1 billion, leading to a significant drop in its stock price [4] Market Challenges - The decline in Covid vaccine sales is attributed to increased competition, falling vaccination rates, and the timing of manufacturing contracts [5] - The company also reported $15 million in U.S. sales of its RSV vaccine, which is approved for seniors [8][10] Future Developments - Moderna submitted three mRNA products for regulatory approval during Q4, including a next-generation Covid shot and a combination shot targeting Covid and flu [11] - The company is developing additional products, including a standalone flu shot and a personalized cancer vaccine, with data readouts expected later this year [12]

Financial Performance - Moderna, Inc. generated $3.0-3.1 billion in product sales for the fiscal year ended December 31, 2024[4] Cash and Investments - The company's cash, cash equivalents, and investments in marketable securities are approximately $9.5 billion as of December 31, 2024[4] Audit Status - The financial information provided is preliminary and unaudited, with ongoing audits that may result in changes[5]

Moderna, Inc. MRNA will release its fourth-quarter financial results, before the opening bell, on Friday, Feb. 14, 2025.Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $2.68 per share, versus earnings of 55 cents per share in the year-ago period. Moderna projects quarterly revenue of $942.84 million, compared to $2.81 billion a year earlier, according to data from Benzinga Pro.The company has topped consensus estimates on the top and bottom lines for the last four co ...

Analysts on Wall Street project that Moderna (MRNA) will announce quarterly loss of $2.65 per share in its forthcoming report, representing a decline of 581.8% year over year. Revenues are projected to reach $956.11 million, declining 66% from the same quarter last year.The current level reflects an upward revision of 7.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over thi ...

Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for long-term investors remains the same: Invest in companies that can perform well over long periods, whether or not they moved in tandem with the market in January. One month of strong (or poor) returns means little in the grand scheme of things.To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this year: Vertex Phar ...

Group 1: Tilray Brands - Tilray has been a speculative investment based on hopes for marijuana legalization in the U.S., but the stock has declined over 94% in five years [3][4] - The company has diversified into alcoholic beverages, yet its financial situation remains precarious, with a market cap below $1 billion [5] - Continuous cash burn and losses indicate a lack of recovery potential for Tilray [5] Group 2: Moderna - Moderna has missed opportunities to diversify beyond its COVID vaccine revenue, focusing instead on COVID-related products [6] - The company expects revenue between $1.5 billion and $2.5 billion for the year, a reduction of approximately $1 billion from previous expectations [8] - There are no clear catalysts for growth, making it a stock to avoid even if prices decline further [9] Group 3: Plug Power - Plug Power's stock has plummeted from over $70 in 2021 to under $2, reflecting investor skepticism [10] - The company faces significant financial challenges, with $94 million in cash and operating losses exceeding $720 million in the first nine months of 2024 [12] - The sustainability of its operations is in question, suggesting that investors should consider other growth opportunities [12]

Group 1: Moderna's Earnings Outlook - Moderna is expected to report a year-over-year decline in earnings, with a projected loss of $2.65 per share, reflecting a change of -581.8% [3][12] - Revenues for the upcoming quarter are anticipated to be $955.23 million, down 66% from the same quarter last year [3] - The earnings report is scheduled for release on February 14, 2025, and could influence stock movement based on whether results exceed or fall short of expectations [2][12] Group 2: Earnings Estimate Revisions - The consensus EPS estimate for Moderna has been revised 7.2% higher in the last 30 days, indicating a more optimistic outlook from analysts [4] - The Most Accurate Estimate for Moderna is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +3.26%, suggesting a likelihood of beating the consensus EPS estimate [10][11] Group 3: Historical Performance and Predictive Indicators - Moderna has a history of beating consensus EPS estimates, having done so in the last four quarters [13] - The predictive power of the Earnings ESP is significant for positive readings, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8] - Despite a positive earnings outlook, other factors may also influence stock performance, making it essential to consider broader market conditions [14][16] Group 4: Industry Comparison - In the Zacks Medical - Biomedical and Genetics industry, Alnylam Pharmaceuticals is expected to post a loss of $0.21 per share, indicating a year-over-year change of +80.9% [17] - Alnylam's revenue is projected to be $570.11 million, up 29.7% from the previous year, but it has an Earnings ESP of -192.68%, complicating predictions for beating the consensus EPS estimate [18]

We expect Moderna (MRNA) to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before the opening bell. In the last reported quarter, MRNA’s earnings beat estimates by 101.59%.The Zacks Consensus Estimate for sales and earnings is pegged at $955.23 million and at a loss of $2.65 per share, respectively. Both metrics indicate a significant decline from the year-ago levels.See the Zacks Earnings Calendar to stay ahead of market-making news.Factors Shaping MRNA’s Upcomi ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.If these pre-market losses hold, Moderna stock could erase part of its 8.1% year-to-date lead and deepen its 57.1% year-over-year loss. The equity may also slip below a critical technical level -- its 20-day moving average -- which could pressure ...